A study of 280,000 U.S. veterans, including 56,000 African Americans, has identified in greater detail than ever before the genetic architecture of kidney function and chronic kidney disease (CKD), according to researchers at Vanderbilt University Medical Center and their colleagues.

The discovery that kidney cells with mutations in a certain gene are sensitive to therapies called PI3K inhibitors opens new opportunities for applying precision medicine to cancer treatment.

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.

A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.

Precision medicine research — which involves the consolidation of massive amounts of complex data and the widespread sharing of those data for a variety of research studies — offers the prospect of both benefit and harm.

The All of Us Research Program, which aims to accelerate the prevention and treatment of illness through precision medicine with the help of a million or more research participants across the United States, officially opens for national enrollment Sunday, May 6.

Consuelo Wilkins, MD, MSCI, has played a major role in the development of the national All of Us Research Program, an ambitious effort led by the National Institutes of Health (NIH) to accelerate the prevention and treatment of illness through precision medicine.